Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

NCT06624189 | Enrolling By Invitation

• 1 other identifier: QI-Active Choice CDS
• Study Type: observational
• Target: 1,300
• Locations: 1 country
• Sites: 1

Brief Summary

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Conditions

Hepatocellular Carcinoma; Cirrhosis

Outcome Measures

Primary Outcomes (1)

• Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound

  Day 1

Secondary Outcomes (2)

• Percentage of Participants with Completed Liver Ultrasound Imaging

  Day 1

• HCC Diagnosis Rate from Completed Liver Ultrasound Imaging

  Day 1

Study Arms (2)

Intervention: Auto-pended bot liver ultrasound order

Participants in the intervention group will receive an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening.

Other: Auto-pended bot liver ultrasound order

Control: Usual Care

Participants in the control group will not receive the auto-pended bot liver ultrasound order.

Interventions

Auto-pended bot liver ultrasound order OTHER

This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Intervention: Auto-pended bot liver ultrasound order

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients presenting with a cirrhosis diagnosis, and at the date of their appointment had been 6 months or more after their most recent imaging.

You may qualify if:

• cirrhosis diagnosis,
• months or more after since most recent imaging.

You may not qualify if:

• previous liver transplant,
• HCC diagnosis,
• receiving hospice care,
• completed external imaging in the past 6 months.

Sponsors & Collaborators

• NYU Langone Health: lead

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Fibrosis

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Saul Blecker

  NYU Langone Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2024
• First Posted: October 2, 2024
• Study Start: November 20, 2024
• Primary Completion: April 24, 2026
• Study Completion (Estimated): July 24, 2026
• Last Updated: February 27, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)